NDLI: An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.

Please wait, while we are loading the content...

A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds.

Pretreatment with flurbiprofen axetil, flurbiprofen axetil preceded by venous occlusion, and a mixture of flurbiprofen axetil and propofol in reducing pain on injection of propofol in adult Japanese surgical patients: a prospective, randomized, double-blind, placebo-controlled study.

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.

Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers.

Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.

Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.

Standing on the shoulders of Mark H. Beers: more than a giant in geriatric medicine.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.

Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.

Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.

The financial implications for Medicare of greater use of peritoneal dialysis.

Modified visual analog scale symptom-intensity and overall-bother measures for the assessment of symptoms in studies of pharmacologic stress agents.

Interpreting treatment-effect estimates with heterogeneity and choice: simulation model results.

Year: 2009 Volume: 31 Issue: 3

Year: 2009 Volume: 31 Issue: 2

Year: 2009 Volume: 31 Issue: Supplementary 2

Year: 2009 Volume: 31 Issue: 1

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Loomba-Albrecht, Lindsey A. Glaser, Nicole S. Styne, Dennis M. Bremer, Andrew A.
Description	Country affiliation: United States Author Affiliation: Loomba-Albrecht LA ( Department of Pediatrics, Division of Endocrinology, University of California Davis Medical Center, Sacramento, California 95817-2208, USA.)
Abstract	BACKGROUND: Neonatal diabetes mellitus (NDM) is rare, with a prevalence of approximately 1 in 500,000 infants worldwide. NDM may be caused by several different genetic abnormalities, and might either be transient (TNDM) or permanent. Until recently, clinical management of most permanent types of NDM required lifelong subcutaneous insulin treatment. However, due to activating mutations in the genes that encode the adenosine triphosphate-sensitive K(+) channel, some permanent types of NDM have been found to be amenable to oral sulfonylurea therapy. TNDM can last for a median of 12 weeks and completely resolve by 18 months. Although TNDM is typically treated with subcutaneous insulin, this mode of therapy might be difficult for some caregivers. CASE SUMMARY: A small for gestational age male infant born at term developed NDM on day of life (DOL) 3. No other factors, such as sepsis, infection, or dextrose-containing intravenous fluids, that could have accounted for the hyperglycemia were present. In addition, there was no family history of DM or hyper-glycemic disorders. The patient was initially treated with subcutaneous regular insulin (0.25 U at a concentration of 10 U/L) q4h PRN for blood glucose concentrations >200 mg/dL. However, due to persistent blood glucose concentration fluctuations, a continuous insulin infusion (0.05 U/kg/h) was started on DOL 7. Because subcutaneous insulin injections could not be administered by the parents outside of the hospital, oral sulfonylurea therapy was attempted. A glyburide oral suspension, prepared by dissolving half of a 1.25-mg tablet in 1 mL of preservative-free, sterile water, was started at 0.2 mg/kg/d in 2 divided doses. The suspension was prepared immediately prior to each dose and was administered via syringe during feedings. On DOL 21, the patient's NDM was managed solely with an oral sulfonylurea, target blood glucose concentrations of 150 to 250 mg/dL were achieved with glyburide 0.7 mg/kg/d in 2 divided doses, and insulin administration was no longer required. On DOL 25, the glyburide dosage was decreased to 0.5 mg/kg/d in 2 divided doses. On DOL 27, the patient was discharged on the same dosage. The patient's NDM subsequently resolved by DOL 49. CONCLUSION: An oral sulfonylurea was a useful treatment option in the management of TNDM in this patient.
File Format	HTM / HTML
ISSN	01492918
Issue Number	4
Volume Number	31
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2009-04-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Diabetes Mellitus Drug Therapy Glyburide Therapeutic Use Hypoglycemic Agents Administration, Oral Blood Glucose Drug Effects Dose-response Relationship, Drug Administration & Dosage Humans Infant, Newborn Infant, Newborn, Diseases Insulin Male Case Reports Journal Article
Content Type	Text
Resource Type	Case study Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A 'picturesque' case of transition from subcutaneous to oral treatment in neonatal diabetes.

Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy.

Diabetes mellitus beim Frühgeborenen: Erstmalige Behandlung mit Sulfonylharnstoff. (Part 1)

Transient neonatal diabetes mellitus in extremely preterm infant.

Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.

Effect of Yanggyuksanhwa-tang on non-insulin-dependent diabetes mellitus unresponsive to oral hypoglycemic agents: a case report.

Diabetes caused by Kir6.2 mutation: successful treatment with oral glibenclamide switched from continuous subcutaneous insulin infusion in the early phase of the disease.

Oral hypoglycemic agents for gestational diabetes mellitus?

Neonatal diabetes and insulin pump therapy.

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.

Similar Documents

A 'picturesque' case of transition from subcutaneous to oral treatment in neonatal diabetes.

Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy.

Diabetes mellitus beim Frühgeborenen: Erstmalige Behandlung mit Sulfonylharnstoff. (Part 1)

Transient neonatal diabetes mellitus in extremely preterm infant.

Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.

Effect of Yanggyuksanhwa-tang on non-insulin-dependent diabetes mellitus unresponsive to oral hypoglycemic agents: a case report.

Diabetes caused by Kir6.2 mutation: successful treatment with oral glibenclamide switched from continuous subcutaneous insulin infusion in the early phase of the disease.

Oral hypoglycemic agents for gestational diabetes mellitus?

Neonatal diabetes and insulin pump therapy.

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.